Virgo Unveils EndoML: The Future of AI for Gastroenterology at DDW 2025
At the recent Digestive Disease Week (DDW) 2025 event in San Diego, Virgo Surgical Video Solutions, Inc., a pioneering company in endoscopic AI technologies, officially introduced EndoML, an advanced artificial intelligence development platform designed to innovate the fields of gastroenterology and pharmaceutical research. With the goal of streamlining the approach from AI concept conception to real-world application, EndoML offers unique solutions tailored specifically for medical professionals.
Most notably, EndoML eliminates the need for extensive coding or machine learning expertise, creating an accessible pathway for researchers aiming to transform raw endoscopic data into viable AI models. This platform leverages Virgo's renowned foundation model, EndoDINO, trained on a comprehensive collection of over 130,000 complete gastrointestinal (GI) endoscopy videos. EndoDINO has already showcased its capabilities through stellar performance in numerous applications, including anatomical landmark identification, polyp segmentation, and assessments of inflammatory bowel disease (IBD) severity.
Matt Schwartz, CEO of Virgo, highlighted the empowering aspect of EndoML during the launch, stating, "The EndoML platform puts the power of artificial intelligence directly into the hands of clinicians and researchers, allowing them to harness the full potential of AI in gastroenterology. Our goal is to democratize AI development in this field, facilitating quicker transitions from conceptual research to tangible patient care improvements." Demonstrations of EndoML were scheduled throughout the event, allowing attendees to witness firsthand how this technology can transform their practices.
An important feature of EndoML is its ability to enable researchers to train AI models using their own proprietary datasets, encouraging unique applications across various scientific studies. By utilizing EndoDINO as a backbone, researchers can anticipate exceptional performance while minimizing the amount of labeled data required. The models developed on this platform will be readily accessible to further enhance collaboration and innovation within the research community.
The accuracy of EndoML has already been validated by Virgo's previous work, which demonstrated its efficacy in assessing Mayo Endoscopic Scoring with precision at both frame-level and video-level analyses. Chris Lawcock, the Vice President of Engineering at Virgo, emphasized the platform's dual utility, stating, "EndoML not only simplifies the AI model development process but also grants pharmaceutical sponsors the flexibility to train and deploy models according to their specifications. These models integrate effortlessly within our VirgoTrials—a dedicated data capture and management solution designed for clinical trials—while also remaining compatible with external data analysis environments."
Attendees at DDW 2025 were invited to explore the transformative power of EndoML during the conference. Virgo offered in-depth demonstrations and personalized consultations to those interested in harnessing AI for their research needs. Interested parties could also register to experience the platform's capabilities firsthand at endoml.ai, enabling a deeper understanding of how this innovation could enhance their work.
It's important to note that both EndoML and EndoDINO are intended strictly for research purposes and are not classified as medical devices. Access to integration within the VirgoTrials clinical research platform is available upon request, and utilizing these tools for clinical decision-making or patient care is not in their intended use. The implications of EndoML suggest a significant shift in practice standards within gastroenterology, heralding a new era of efficiency and accuracy that stands to benefit both clinicians and researchers alike.
With EndoML, Virgo Surgical Video Solutions has certainly made a notable mark in the progression of AI technologies in the healthcare sector, epitomizing their commitment to advancing medical research and patient outcomes.
Most notably, EndoML eliminates the need for extensive coding or machine learning expertise, creating an accessible pathway for researchers aiming to transform raw endoscopic data into viable AI models. This platform leverages Virgo's renowned foundation model, EndoDINO, trained on a comprehensive collection of over 130,000 complete gastrointestinal (GI) endoscopy videos. EndoDINO has already showcased its capabilities through stellar performance in numerous applications, including anatomical landmark identification, polyp segmentation, and assessments of inflammatory bowel disease (IBD) severity.
Matt Schwartz, CEO of Virgo, highlighted the empowering aspect of EndoML during the launch, stating, "The EndoML platform puts the power of artificial intelligence directly into the hands of clinicians and researchers, allowing them to harness the full potential of AI in gastroenterology. Our goal is to democratize AI development in this field, facilitating quicker transitions from conceptual research to tangible patient care improvements." Demonstrations of EndoML were scheduled throughout the event, allowing attendees to witness firsthand how this technology can transform their practices.
An important feature of EndoML is its ability to enable researchers to train AI models using their own proprietary datasets, encouraging unique applications across various scientific studies. By utilizing EndoDINO as a backbone, researchers can anticipate exceptional performance while minimizing the amount of labeled data required. The models developed on this platform will be readily accessible to further enhance collaboration and innovation within the research community.
The accuracy of EndoML has already been validated by Virgo's previous work, which demonstrated its efficacy in assessing Mayo Endoscopic Scoring with precision at both frame-level and video-level analyses. Chris Lawcock, the Vice President of Engineering at Virgo, emphasized the platform's dual utility, stating, "EndoML not only simplifies the AI model development process but also grants pharmaceutical sponsors the flexibility to train and deploy models according to their specifications. These models integrate effortlessly within our VirgoTrials—a dedicated data capture and management solution designed for clinical trials—while also remaining compatible with external data analysis environments."
Attendees at DDW 2025 were invited to explore the transformative power of EndoML during the conference. Virgo offered in-depth demonstrations and personalized consultations to those interested in harnessing AI for their research needs. Interested parties could also register to experience the platform's capabilities firsthand at endoml.ai, enabling a deeper understanding of how this innovation could enhance their work.
It's important to note that both EndoML and EndoDINO are intended strictly for research purposes and are not classified as medical devices. Access to integration within the VirgoTrials clinical research platform is available upon request, and utilizing these tools for clinical decision-making or patient care is not in their intended use. The implications of EndoML suggest a significant shift in practice standards within gastroenterology, heralding a new era of efficiency and accuracy that stands to benefit both clinicians and researchers alike.
With EndoML, Virgo Surgical Video Solutions has certainly made a notable mark in the progression of AI technologies in the healthcare sector, epitomizing their commitment to advancing medical research and patient outcomes.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.